Cargando…
Epithelial to mesenchymal transition in the liver field: the double face of Everolimus in vitro
BACKGROUND: Everolimus (EVE), a mammalian target of rapamycin inhibitor, has been proposed as liver transplant immunosuppressive drug, gaining wide interest also for the treatment of cancer. Although an appropriate tolerance, it may induce several adverse effects, such as fibro-interstitial pneumoni...
Autores principales: | Masola, Valentina, Carraro, Amedeo, Zaza, Gianluigi, Bellin, Gloria, Montin, Umberto, Violi, Paola, Lupo, Antonio, Tedeschi, Umberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570634/ https://www.ncbi.nlm.nih.gov/pubmed/26369804 http://dx.doi.org/10.1186/s12876-015-0347-6 |
Ejemplares similares
-
In vitro effects of interleukin (IL)-1 beta inhibition on the epithelial-to-mesenchymal transition (EMT) of renal tubular and hepatic stellate cells
por: Masola, Valentina, et al.
Publicado: (2019) -
Everolimus-induced epithelial to mesenchymal transition in immortalized human renal proximal tubular epithelial cells: key role of heparanase
por: Masola, Valentina, et al.
Publicado: (2013) -
A new mechanism of action of sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2-induced renal epithelial-mesenchymal transition
por: Masola, Valentina, et al.
Publicado: (2012) -
Heparanase: A Potential New Factor Involved in the Renal Epithelial Mesenchymal Transition (EMT) Induced by Ischemia/Reperfusion (I/R) Injury
por: Masola, Valentina, et al.
Publicado: (2016) -
Sirolimus and Everolimus Pathway: Reviewing Candidate Genes Influencing Their Intracellular Effects
por: Granata, Simona, et al.
Publicado: (2016)